SARS-CoV-2 rS antigen/Matrix-M Adjuvant

Drug identity checked against registry records

Also recorded as Updated Novavax COVID-19 vaccine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNCT05875701NovavaxPhase 3Completed2023-11-11Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.